Article
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Journal of virology - 1 Sept 1996
Larder B A, Kohli A, Bloor S, Kemp S D, Harrigan P R, Schooley R T, Lange J M, Pennington K N, St Clair M H
Abstract excerpt
Human immunodeficiency virus type 1 (HIV-1) isolates obtained prior to and during a combination therapy trial comparing zidovudine (AZT; 3'-azidothymidine) monotherapy with AZT plus 2',3'-dideoxyinosine (ddI) or AZT plus 2',3'-dideoxycytidine (ddC) were assessed for the development of drug resistance. Drug susceptibility was measured by using two different phenotypic assays, one that requires infection of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.